Tillotts Standardizes on Veeva Commercial Cloud Applications to Power Digital Engagement in Europe

Veeva Systems  announced that Tillotts Pharma AG is using Veeva CRM and Veeva Vault PromoMats to advance digital engagement in France, Germany, Italy, Spain, and the United Kingdom. With these connected Veeva Commercial Cloud applications, the company can better coordinate relevant interactions with healthcare professionals (HCPs), delivering tailored and compliant multi-channel content.

“With Veeva CRM and Veeva Vault PromoMats we gain a complete view of customers and content to enable relevant engagement across Europe,” said Adrian Hill, global head of commercial operations at Tillotts. “We can now use real-time insights to quickly adapt and deliver the precise information needed for HCPs in each market.”

Also Read: Highspot’s Culture Drives Revenue Growth And Top Tier Recognition

Tillotts has been accelerating expansion into Europe since 2020 when it acquired a new product for the treatment of gastro-intestinal infections. As part of its digital engagement strategy, Tillotts is also using Veeva OpenData, embedding healthcare ecosystem reference data in Veeva CRM for real-time insights.

“Tillotts is leading the way toward commercial excellence, creating seamless collaboration between sales, medical, and marketing to better serve its customers,” said Philipp Luik, vice president of commercial strategy at Veeva Europe. “With Veeva CRM and Veeva Vault PromoMats working hand in hand, field teams have the engine to drive meaningful interactions.”

Vault PromoMats combines digital asset management with medical, legal, and regulatory review to improve global reuse of content and maintain compliance from creation to distribution via multiple channels. Find out more about how Veeva is helping life sciences companies improve their customer experience through digital engagement.

Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 300 employees in Switzerland and abroad. Tillotts is dedicated to the development, acquisition, and commercialisation of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD and Clostridioides difficile infection (CDI) as well as in-licensed products in around 65 countries through its affiliates within Europe and a network of gastroenterology-focused partners throughout the world.